Type 3 Von Willebrand International Registries Inhibitor Prospective Study

Plain-language summary

This study followed individuals with type 3 von Willebrand disease through an international registry to investigate inhibitors (antibodies) that can develop against the von Willebrand factor used in treatment. It enrolled patients of all ages, including infants, with a previously confirmed diagnosis. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Fondazione Angelo Bianchi Bonomi

Intervention

Von Willebrand Factor

Start date

11/5/2012

Estimated completion

4/17/2023

Countries

Finland, France, Germany, Hungary, Iran, Italy, Netherlands, Spain, Sweden, United Kingdom

Related genes

Locations

• Helsinki, Finland
• Lille, France
• Nantes, France
• Bonn, Germany
• Hamburg, Germany
• Hanover, Germany
• Budapest, Hungary
• Ahvāz, Iran
• Isfahan, Iran
• Mashhad, Iran
• Shiraz, Iran
• Tehran, Iran
• Tehran, Iran
• Tehran, Iran
• Bari, Italy
• Florence, Italy
• Milan, Italy
• Roma, Italy
• Vicenza, Italy
• Leiden, Netherlands
• Rotterdam, Netherlands
• A Coruña, Spain
• Barcelona, Spain
• Malmö, Sweden
• Manchester, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male and female of any age, including infants, children, adolescent and adults
* Informed Consent obtained (parents should sign for patients \< 18 y.o.)
* Previous Diagnosis of VWD3 (VWF Antigen: undetectable or \<5 U/dL)
* Detailed information on inherited pattern, history of bleeding, previous exposure to blood products
* Availability of plasma and DNA samples

Exclusion Criteria:

• VWD3 patients who may not be available for follow-up